Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Julia Durbeck"'
Publikováno v:
PeerJ, Vol 9, p e10892 (2021)
The Doublesex/Mab-3 Domain transcription factor DMD-10 is expressed in several cell types in C. elegans, including in the nervous system. We sought to investigate whether DMD-10 is required for normal neuronal function using behavioral assays. We fou
Externí odkaz:
https://doaj.org/article/bd70e83d53124c80ab4e3c963e063367
Publikováno v:
PeerJ
PeerJ, Vol 9, p e10892 (2021)
PeerJ, Vol 9, p e10892 (2021)
The Doublesex/Mab-3 Domain transcription factor DMD-10 is expressed in several cell types in C. elegans, including in the nervous system. We sought to investigate whether DMD-10 is required for normal neuronal function using behavioral assays. We fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4002c07c5d8c9aa392303cabf6e22f3
http://europepmc.org/articles/PMC7916532
http://europepmc.org/articles/PMC7916532
Publikováno v:
Oral oncology. 108
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0b104a6de06bef5344a3628bc65ef4
https://pubmed.ncbi.nlm.nih.gov/32792211
https://pubmed.ncbi.nlm.nih.gov/32792211
Publikováno v:
Oral oncology. 111
Objectives To examine the impact of treatment sequences of Immune checkpoint inhibitor (ICI) and cetuximab on clinical outcomes in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Materials and methods Clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d470feb7739d8b030eb7da29ffb668
https://pubmed.ncbi.nlm.nih.gov/33065374
https://pubmed.ncbi.nlm.nih.gov/33065374
Publikováno v:
Oral Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344818996692152b65aadab49bbc5b2e
https://doi.org/10.1016/j.oraloncology.2020.104776
https://doi.org/10.1016/j.oraloncology.2020.104776
Autor:
Karim Boudadi, Julia Durbeck, Won Jin Ho, Hyunseok Kang, Lori J. Wirth, John W. Clark, Jong Chul Park
Publikováno v:
Journal of Clinical Oncology. 38:6538-6538
6538 Background: The current standard treatment for unresectable recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) is cytotoxic chemotherapy but prognosis remains poor. Recent phase I-II trials of anti-PD-1 therapy (aPD-1) have demonstrated p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dcb19658d710c4a53e8463faedfa288
https://doi.org/10.1200/jco.2020.38.15_suppl.6538
https://doi.org/10.1200/jco.2020.38.15_suppl.6538